Multiple Origins of Mutations in the mdr1 Gene—A Putative Marker of Chloroquine Resistance in P. vivax

Background Chloroquine combined with primaquine has been the recommended antimalarial treatment of Plasmodium vivax malaria infections for six decades but the efficacy of this treatment regimen is threatened by chloroquine resistance (CQR). Single nucleotide polymorphisms (SNPs) in the multidrug resistance gene, Pvmdr1 are putative determinants of CQR but the extent of their emergence at population level remains to be explored. Objective In this study we describe the prevalence of SNPs in the Pvmdr1 among samples collected in seven P. vivax endemic countries and we looked for molecular evidence of drug selection by characterising polymorphism at microsatellite (MS) loci flanking the Pvmdr1 gene. Methods We examined the prevalence of SNPs in the Pvmdr1 gene among 267 samples collected from Pakistan, Afghanistan, Sri Lanka, Nepal, Sudan, São Tomé and Ecuador. We measured and diversity in four microsatellite (MS) markers flanking the Pvmdr1 gene to look evidence of selection on mutant alleles. Results SNP polymorphism in the Pvmdr1 gene was largely confined to codons T958M, Y976F and F1076L. Only 2.4% of samples were wildtype at all three codons (TYF, n = 5), 13.3% (n = 28) of the samples were single mutant MYF, 63.0% of samples (n = 133) were double mutant MYL, and 21.3% (n = 45) were triple mutant MFL. Clear geographic differences in the prevalence of these Pvmdr mutation combinations were observed. Significant linkage disequilibrium (LD) between Pvmdr1 and MS alleles was found in populations sampled in Ecuador, Nepal and Sri Lanka, while significant LD between Pvmdr1 and the combined 4 MS locus haplotype was only seen in Ecuador and Sri Lanka. When combining the 5 loci, high level diversity, measured as expected heterozygosity (He), was seen in the complete sample set (He = 0.99), while He estimates for individual loci ranged from 0.00–0.93. Although Pvmdr1 haplotypes were not consistently associated with specific flanking MS alleles, there was significant differentiation between geographic sites which could indicate directional selection through local drug pressure. Conclusions Our observations suggest that Pvmdr1 mutations emerged independently on multiple occasions even within the same population. In Sri Lanka population analysis at multiple sites showed evidence of local selection and geographical dispersal of Pvmdr1 mutations between sites.

[1]  M. Rowland,et al.  Global and local genetic diversity at two microsatellite loci in Plasmodium vivax parasites from Asia, Africa and South America , 2014, Malaria Journal.

[2]  L. Seidlein,et al.  Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis , 2014, The Lancet. Infectious diseases.

[3]  D. Ménard,et al.  The Evolutionary History of Plasmodium vivax as Inferred from Mitochondrial Genomes: Parasite Genetic Diversity in the Americas , 2013, Molecular biology and evolution.

[4]  A. Dash,et al.  The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum , 2012, Nature Genetics.

[5]  Badria B. El-Sayed,et al.  Increased pfmdr1 Copy Number and Sequence Polymorphisms in Plasmodium falciparum Isolates from Sudanese Malaria Patients Treated with Artemether-Lumefantrine , 2011, Antimicrobial Agents and Chemotherapy.

[6]  Young Keun Kim,et al.  Therapeutic efficacy of chloroquine in Plasmodium vivax and the pvmdr1 polymorphisms in the Republic of Korea under mass chemoprophylaxis. , 2011, The American journal of tropical medicine and hygiene.

[7]  I. Bygbjerg,et al.  Prevalence of molecular markers of anti-malarial drug resistance in Plasmodium vivax and Plasmodium falciparum in two districts of Nepal , 2011, Malaria Journal.

[8]  J. Sattabongkot,et al.  Genetic polymorphism in pvmdr1 and pvcrt-o genes in relation to in vitro drug susceptibility of Plasmodium vivax isolates from malaria-endemic countries. , 2011, Acta tropica.

[9]  C. Daniel-Ribeiro,et al.  Characterisation of pvmdr1 and pvdhfr genes associated with chemoresistance in Brazilian Plasmodium vivax isolates. , 2009, Memorias do Instituto Oswaldo Cruz.

[10]  A. Maestre,et al.  Assessment of the origins and spread of putative resistance-conferring mutations in Plasmodium vivax dihydropteroate synthase. , 2009, The American journal of tropical medicine and hygiene.

[11]  J. Baird Resistance to Therapies for Infection by Plasmodium vivax , 2009, Clinical Microbiology Reviews.

[12]  H. D. del Portillo,et al.  Analysis of Single-Nucleotide Polymorphisms in the crt-o and mdr1 Genes of Plasmodium vivax among Chloroquine-Resistant Isolates from the Brazilian Amazon Region , 2009, Antimicrobial Agents and Chemotherapy.

[13]  B. Sharp,et al.  Multiple Origins and Regional Dispersal of Resistant dhps in African Plasmodium falciparum Malaria , 2009, PLoS medicine.

[14]  R. Price,et al.  Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. , 2008, The Journal of infectious diseases.

[15]  D. Ménard,et al.  Plasmodium vivax Resistance to Chloroquine in Madagascar: Clinical Efficacy and Polymorphisms in pvmdr1 and pvcrt-o Genes , 2008, Antimicrobial Agents and Chemotherapy.

[16]  M. Rowland,et al.  A Randomised Trial of an Eight-Week, Once Weekly Primaquine Regimen to Prevent Relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan , 2008, PloS one.

[17]  H. Joshi,et al.  Multiple origins of resistance-conferring mutations in Plasmodium vivax dihydrofolate reductase , 2008, Malaria Journal.

[18]  P. Newton,et al.  Gene Amplification of the Multidrug Resistance 1 Gene of Plasmodium vivax Isolates from Thailand, Laos, and Myanmar , 2008, Antimicrobial Agents and Chemotherapy.

[19]  R. Price,et al.  Chloroquine Resistant Plasmodium vivax: In Vitro Characterisation and Association with Molecular Polymorphisms , 2007, PloS one.

[20]  M. Rowland,et al.  Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. , 2007, JAMA.

[21]  I. Bygbjerg,et al.  Island-wide diversity in single nucleotide polymorphisms of the Plasmodium vivax dihydrofolate reductase and dihydropteroate synthetase genes in Sri Lanka , 2007, Malaria Journal.

[22]  M. Milinkovitch,et al.  Estimating population parameters using the structured serial coalescent with Bayesian MCMC inference when some demes are hidden. , 2007 .

[23]  L. Tilley,et al.  Primaquine synergises the activity of chloroquine against chloroquine-resistant P. falciparum. , 2005, Biochemical pharmacology.

[24]  B. Sharp,et al.  Reduced variation around drug-resistant dhfr alleles in African Plasmodium falciparum. , 2005, Molecular biology and evolution.

[25]  Manoj T Duraisingh,et al.  Contribution of the pfmdr1 gene to antimalarial drug-resistance. , 2005, Acta tropica.

[26]  Danny W. Wilson,et al.  Origin and Dissemination of Chloroquine-Resistant Plasmodium falciparum with Mutant pfcrt Alleles in the Philippines , 2005, Antimicrobial Agents and Chemotherapy.

[27]  H. D. del Portillo,et al.  Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. , 2005, Experimental parasitology.

[28]  L. Gradoni,et al.  Identification of the Plasmodium vivax mdr-like gene (pvmdr1) and analysis of single-nucleotide polymorphisms among isolates from different areas of endemicity. , 2005, The Journal of infectious diseases.

[29]  B. Sharp,et al.  Intercontinental Spread of Pyrimethamine-Resistant Malaria , 2004, Science.

[30]  R. Udomsangpetch,et al.  Real-Time PCR for Dihydrofolate Reductase Gene Single-Nucleotide Polymorphisms in Plasmodium vivax Isolates , 2004, Antimicrobial Agents and Chemotherapy.

[31]  P. Newton,et al.  A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. , 2003, Molecular biology and evolution.

[32]  B. Sharp,et al.  Antifolate antimalarial resistance in southeast Africa: a population-based analysis , 2003, The Lancet.

[33]  C. Plowe,et al.  Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. , 2002, The Journal of infectious diseases.

[34]  John C. Wootton,et al.  Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum , 2002, Nature.

[35]  J. Wootton,et al.  Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. , 2001, The Journal of infectious diseases.

[36]  D. Warhurst A molecular marker for chloroquine-resistant falciparum malaria. , 2001, The New England journal of medicine.

[37]  X. Su,et al.  A molecular marker for chloroquine-resistant falciparum malaria. , 2001, The New England journal of medicine.

[38]  J. Wootton,et al.  Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. , 2000, Molecular cell.

[39]  M. Duraisingh,et al.  The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. , 2000, Molecular and biochemical parasitology.

[40]  F. López-Antuñano Is primaquine useful and safe as true exo-erythrocytic merontocidal, hypnozoitocidal and gametocidal antimalarial drug? , 1999, Salud publica de Mexico.

[41]  A. Cowman,et al.  Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum , 1990, Nature.

[42]  K. Rieckmann,et al.  PLASMODIUM VIVAX RESISTANCE TO CHLOROQUINE? , 1989, The Lancet.

[43]  Rakitzis Et,et al.  ENZYME-STRIP ESTIMATION OF BLOOD-GLUCOSE. , 1964 .

[44]  G. Coatney,et al.  Korean vivax malaria. II. Curative treatment with pamaquine and primaquine. , 1953, The American journal of tropical medicine and hygiene.

[45]  G. Benson,et al.  Tandem repeats finder: a program to analyze DNA sequences. , 1999, Nucleic acids research.

[46]  A. Tarlov,et al.  Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report. , 1960, Bulletin of the World Health Organization.